Skip to main content

Advertisement

Table 4 Distribution of tumor phenotypes among screening-detected cancers (n = 1,297) and categories of interval cancers (n = 948) stratified by breast density

From: Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain

  Breast density  
  <25% 25 to 50% 50 to 75% >75% P-value
Tumor phenotype      
Screening-detected cancers     
Luminal A 247 (68.6) 165 (65.5) 142 (70.3) 75 (71.4)  
Luminal B 51 (36.7) 49 (19.3) 24 (11.9) 15 (14.3)  
HER2 20 (5.6) 16 (6.3) 17 (8.4) 9 (8.6)  
Triple negative 42 (11.7) 24 (9.4) 19 (9.4) 6 (5.7)  
Unknown 150 105 25 46 0.306
True interval cancers    
Luminal A 60 (52.2) 51 (45.5) 49 (50.5) 37 (58.7)  
Luminal B 13 (11.3) 17 (15.2) 15 (15.5) 15 (23.8)  
HER2 9 (7.8) 20 (17.9) 22 (22.7)* 2 (3.2)*  
Triple negative 33 (28.7)* 24 (21.4) 11 (11.3) 9 (14.3)  
Unknown 24 15 17 12 <0.001
False negatives      
Luminal A 40 (62.5) 39 (75.0) 22 (64.7) 23 (71.9)  
Luminal B 10 (15.6) 4 (7.7) 9 (26.5) 6 (18.8)  
HER2 6 (9.4) 4 (7.7) 2 (5.9) 2 (6.3)  
Triple negative 8 (12.5) 5 (9.6) 1 (2.9) 1 (3.1)  
Unknown 17 8 11 6 0.375
Minimal-sign cancers     
Luminal A 30 (60.0) 26 (66.7) 16 (55.2) 7 (46.7)  
Luminal B 6 (12.0) 3 (7.7) 5 (17.2) 4 (26.7)  
HER2 2 (4.0) 5 (12.8) 2 (6.9) 4 (26.7)  
Triple negative 12 (24.0) 5 (12.8) 6 (20.7) 0 (0)  
Unknown 14 8 10 1 0.081
Occult tumors      
Luminal A 8 (80.0) 12 (80.0) 26 (78.8) 16 (80.0)  
Luminal B 0 (0) 2 (13.3) 4 (12.1) 2 (10.0)  
HER2 0 (0) 1 (6.7) 0 (0) 2 (10.0)  
Triple negative 2 (20.0) 0 (0) 3 (9.1) 0 (0)  
Unknown 5 5 6 9 0.296
  1. Results are expressed as number (%). Tumor phenotypes = Luminal A (ER+/HER2- or PR+/HER2-); Luminal B (ER+/HER2+ or PR+/HER2+); HER2 (ER-/PR-/HER2+); Triple-negative (ER-/PR-/HER2-). *Standardized Pearson residuals with statistically significant deviation between observed and expected values. P-value assesses the distribution of tumor phenotype distribution among breast density categories within study groups, using the two-sided Chi-square test, or Fisher exact test when appropriate. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.